Altimmune reports Phase 2 results for pemvidutide in alcohol use disorder, plans FDA meeting in December

Altimmune reported Phase 2 results for pemvidutide in alcohol use disorder and plans an FDA meeting in December ahead of Phase 3 development.

Detected & updated continuously · Source: Nebula